Indian stocks: Visit www.stage2stocks.com →

Fulcrum Therapeutics, Inc.

Stage 1 · Basing · week 7

As of Oct 22, 2026, Fulcrum Therapeutics is in Stage 1, the basing phase, now in week 7 (since Sep 9, 2026). It closed at $3.68, 74.8% below its 52-week high and below its 200-day average, which is falling.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical n… More about the company

$3.68
-0.54% today
$281M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is FULC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 20w
S2 21w
S4 22w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 10w → S4 5w → S3 1w → S2 20w → S3 12w → S2 8w → S3 1w → S4 12w → S1 11w → S4 9w → S1 3w → S2 12w → S3 5w → S2 21w → S3 6w → S4 22w → S1 6w current
Total tracked: 165 weeks across 17 stage runs.

FULC among Biotechnology400th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…400FULCStage 1 · wk 718−3.4%
vs 52W High
-74.8%
$3.14 lo$14.60 hi
74.8% below 52W high
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 7
1w13w26w
Week 7, early base
How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.
vs 200 DMA
-39.2%
200 DMA: $6.05 · sloping down
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
1.50x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-3.4%
3M
-1.1%
6M
-54.5%
YTD
-66.3%
1Y
-62.1%
Scan Membership
Breakout Watch
Latest: 2025-06-02
6 appearances in last 60 days. First seen: 2020-05-28.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S1
Wk 7 · Vol 1.50x
2026-10-21S1
Wk 7 · Vol 0.55x
2026-10-20S1
Wk 6 · Vol 0.49x
2026-10-19S1
Wk 6 · Vol 0.77x
2026-10-16S1
Wk 6 · Vol 0.90x
2026-10-15S1
Wk 6 · Vol 0.79x
2026-10-14S1
Wk 6 · Vol 1.06x
2026-10-13S1
Wk 5 · Vol 0.92x
2026-10-12S1
Wk 5 · Vol 1.00x
2026-10-09S1
Wk 5 · Vol 1.12x
2026-10-08S1
Wk 5 · Vol 1.67x
2026-10-07S1
Wk 5 · Vol 0.66x
Moving averages & range
50 DMA
$3.77
200 DMA
$6.05
52W High
$14.60
52W Low
$3.14
5D Low
$3.65
Resistance levels (recent highs)
20d High
$3.77
60d High
$3.91
120d High
$7.25
250d High
$14.60
Next resistance
+2.4%
to 20d High
ROE
-32.4%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.9

Fulcrum Therapeutics: quick answers

What stage is Fulcrum Therapeutics in?

As of Oct 22, 2026, Fulcrum Therapeutics (FULC) is in Stage 1, the basing phase. It entered Stage 1 on Sep 9, 2026 and is in week 7. What the four stages mean

Is Fulcrum Therapeutics in an uptrend?

Not yet. Fulcrum Therapeutics is in Stage 1, a base that can come before an uptrend. It trades 39.2% below its 200-day average, which is falling.

How far is Fulcrum Therapeutics from its 52-week high?

Fulcrum Therapeutics closed at $3.68 on Oct 22, 2026, 74.8% below its 52-week high of $14.60. Its 52-week low is $3.14.

How has Fulcrum Therapeutics performed over the past year?

As of Oct 22, 2026, Fulcrum Therapeutics is down 62.1% over the past year and down 66.3% so far in 2026.

Which sector and industry is Fulcrum Therapeutics in?

Fulcrum Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.